×
S&P 500   4,126.67 (+1.70%)
DOW   32,964.30 (+1.00%)
QQQ   306.72 (+2.47%)
AAPL   148.22 (+3.09%)
MSFT   271.12 (+1.96%)
FB   193.82 (+1.14%)
GOOGL   2,233.14 (+3.59%)
AMZN   2,260.00 (+1.73%)
TSLA   751.01 (+6.12%)
NVDA   185.64 (+3.99%)
BABA   93.02 (-1.55%)
NIO   16.33 (+1.87%)
AMD   100.75 (+2.03%)
CGC   4.88 (-12.07%)
MU   72.73 (+3.02%)
T   21.24 (-0.38%)
GE   77.73 (+0.93%)
F   13.52 (+3.05%)
DIS   108.27 (+2.52%)
AMC   13.58 (+11.04%)
PFE   53.56 (-0.80%)
PYPL   84.98 (+5.67%)
NFLX   194.17 (+1.45%)
S&P 500   4,126.67 (+1.70%)
DOW   32,964.30 (+1.00%)
QQQ   306.72 (+2.47%)
AAPL   148.22 (+3.09%)
MSFT   271.12 (+1.96%)
FB   193.82 (+1.14%)
GOOGL   2,233.14 (+3.59%)
AMZN   2,260.00 (+1.73%)
TSLA   751.01 (+6.12%)
NVDA   185.64 (+3.99%)
BABA   93.02 (-1.55%)
NIO   16.33 (+1.87%)
AMD   100.75 (+2.03%)
CGC   4.88 (-12.07%)
MU   72.73 (+3.02%)
T   21.24 (-0.38%)
GE   77.73 (+0.93%)
F   13.52 (+3.05%)
DIS   108.27 (+2.52%)
AMC   13.58 (+11.04%)
PFE   53.56 (-0.80%)
PYPL   84.98 (+5.67%)
NFLX   194.17 (+1.45%)
S&P 500   4,126.67 (+1.70%)
DOW   32,964.30 (+1.00%)
QQQ   306.72 (+2.47%)
AAPL   148.22 (+3.09%)
MSFT   271.12 (+1.96%)
FB   193.82 (+1.14%)
GOOGL   2,233.14 (+3.59%)
AMZN   2,260.00 (+1.73%)
TSLA   751.01 (+6.12%)
NVDA   185.64 (+3.99%)
BABA   93.02 (-1.55%)
NIO   16.33 (+1.87%)
AMD   100.75 (+2.03%)
CGC   4.88 (-12.07%)
MU   72.73 (+3.02%)
T   21.24 (-0.38%)
GE   77.73 (+0.93%)
F   13.52 (+3.05%)
DIS   108.27 (+2.52%)
AMC   13.58 (+11.04%)
PFE   53.56 (-0.80%)
PYPL   84.98 (+5.67%)
NFLX   194.17 (+1.45%)
S&P 500   4,126.67 (+1.70%)
DOW   32,964.30 (+1.00%)
QQQ   306.72 (+2.47%)
AAPL   148.22 (+3.09%)
MSFT   271.12 (+1.96%)
FB   193.82 (+1.14%)
GOOGL   2,233.14 (+3.59%)
AMZN   2,260.00 (+1.73%)
TSLA   751.01 (+6.12%)
NVDA   185.64 (+3.99%)
BABA   93.02 (-1.55%)
NIO   16.33 (+1.87%)
AMD   100.75 (+2.03%)
CGC   4.88 (-12.07%)
MU   72.73 (+3.02%)
T   21.24 (-0.38%)
GE   77.73 (+0.93%)
F   13.52 (+3.05%)
DIS   108.27 (+2.52%)
AMC   13.58 (+11.04%)
PFE   53.56 (-0.80%)
PYPL   84.98 (+5.67%)
NFLX   194.17 (+1.45%)
LON:OKYO

OKYO Pharma (OKYO) Share Forecast, Price & News

GBX 2.76
-0.09 (-3.16%)
(As of 05/27/2022 02:36 PM ET)
Add
Compare
Today's Range
2.76
2.98
50-Day Range
2.85
7.15
52-Week Range
2.75
9
Volume
175,255 shs
Average Volume
278,663 shs
Market Capitalization
£37.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive OKYO News and Ratings via Email

Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

OKYO Pharma logo

About OKYO Pharma

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.36 per share
Book Value
GBX 0.40 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
1,374,405,000
Free Float
N/A
Market Cap
£37.93 million
Optionable
Not Optionable

Company Calendar

Today
5/27/2022
Next Earnings (Estimated)
8/01/2022

MarketRank

Overall MarketRank

1.19 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













OKYO Pharma (LON:OKYO) Frequently Asked Questions

When is OKYO Pharma's next earnings date?

OKYO Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for OKYO Pharma
.

Who are OKYO Pharma's key executives?
OKYO Pharma's management team includes the following people:
  • Dr. Gary S. Jacob Ph.D., CEO & Exec. Director (Age 75, Pay $290.84k)
  • Mr. Michael Paul Beck, Founder (Age 65)
  • Ms. Keeren Shah, Chief Financial Officer (Age 45)
  • Dr. Rajkumar Patil Ph.D., Chief Scientific Officer (Age 64)
What is OKYO Pharma's stock symbol?

OKYO Pharma trades on the London Stock Exchange (LON) under the ticker symbol "OKYO."

How do I buy shares of OKYO Pharma?

Shares of OKYO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is OKYO Pharma's stock price today?

One share of OKYO stock can currently be purchased for approximately GBX 2.76.

How much money does OKYO Pharma make?

OKYO Pharma has a market capitalization of £37.93 million.

How many employees does OKYO Pharma have?

OKYO Pharma employs 6 workers across the globe.

What is OKYO Pharma's official website?

The official website for OKYO Pharma is www.okyopharma.com.

How can I contact OKYO Pharma?

The company can be reached via phone at 44 20 7495 2379.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.